A REVOLUTIONARY GENERICS (BIOSIMILARS)

Authors

  • Ishan G*, Aashima H, Arun Nanda, Shashank G

Abstract

Biosimilar , or similar biological medicinal products, are used to describe officially approved new versions or generic version of innovative patented biologically active pharmaceutical products referring to existing ones which have been submitted to regulatory authorities for marketing authorization by an independent applicant after the time of protection of the data has expired for the original products. In other words they are "small-molecule" biological drugs,which generally exhibit high molecular complexity, are quite sensitive to manufacturing process and other changes made during their development from original patented drug molecule, e.g. the patent of the first approved recombinant drugs e.g. insulin, human growth hormone, interferons, erythropoietin etc. The terms biogeneric, second entry biological, subsequent entry biological, non-patented biological product and multisource product have also been used for these substances but the EMEA (European Agency for the Evaluation of Medicinal Products) prefers the term biosimilar (the FDA coined the term “follow-on biologicâ€). Biopharmaceuticals are proteins with considerable therapeutic and structural diversity. They tend to be between 100 and 1000 times larger than traditional small molecule drugs

Downloads

Published

2014-02-23

How to Cite

Shashank G, I. G. A. H. A. N. (2014). A REVOLUTIONARY GENERICS (BIOSIMILARS). Journal of Pharmaceutical Research and Opinion, 1(5). Retrieved from http://innovativejournal.in/index.php/jpro/article/view/673

Issue

Vol. 1 No. 5 (2011): JOURNAL OF PHARMACEUTICAL RESEARCH AND OPINION

Section

Articles

License

“I ……………………………………….certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”